WO2015020769A3 - Controllable nucleic acid delivery systems - Google Patents

Controllable nucleic acid delivery systems Download PDF

Info

Publication number
WO2015020769A3
WO2015020769A3 PCT/US2014/046946 US2014046946W WO2015020769A3 WO 2015020769 A3 WO2015020769 A3 WO 2015020769A3 US 2014046946 W US2014046946 W US 2014046946W WO 2015020769 A3 WO2015020769 A3 WO 2015020769A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
delivery systems
delivery
delivery system
acid delivery
Prior art date
Application number
PCT/US2014/046946
Other languages
French (fr)
Other versions
WO2015020769A2 (en
Inventor
Daniel B. HAYES
Original Assignee
Hayes Daniel B
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hayes Daniel B filed Critical Hayes Daniel B
Publication of WO2015020769A2 publication Critical patent/WO2015020769A2/en
Publication of WO2015020769A3 publication Critical patent/WO2015020769A3/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A controllable delivery system is provided, which may be used for controlled delivery of chemicals such as nucleic acids. The delivery system may be light activated and may be useful for controlled delivery of miRNA molecules. The delivery system may be useful for promoting healing and/or wound repair. The delivery system may be used for delivery of miRNA molecules to sites in need of repair and may be used to promote differentiation of stem cells, such as mesenchymal stromal cells.
PCT/US2014/046946 2013-07-19 2014-07-17 Controllable nucleic acid delivery systems WO2015020769A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361856277P 2013-07-19 2013-07-19
US61/856,277 2013-07-19

Publications (2)

Publication Number Publication Date
WO2015020769A2 WO2015020769A2 (en) 2015-02-12
WO2015020769A3 true WO2015020769A3 (en) 2015-04-02

Family

ID=52001047

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/046946 WO2015020769A2 (en) 2013-07-19 2014-07-17 Controllable nucleic acid delivery systems

Country Status (1)

Country Link
WO (1) WO2015020769A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016206491A1 (en) * 2015-01-16 2017-08-31 University Of Iowa Research Foundation Methods to prevent or treat periodontitis or peri-implantitis
US11904006B2 (en) 2019-12-11 2024-02-20 University Of Iowa Research Foundation Poly(diaminosulfide) particle-based vaccine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009045457A2 (en) * 2007-10-02 2009-04-09 Rxi Pharmaceuticals Corp. Tripartite rnai constructs
WO2011133925A2 (en) * 2010-04-23 2011-10-27 Massachusetts Institute Of Technology Targeted and light-activated cytosolic drug delivery

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009045457A2 (en) * 2007-10-02 2009-04-09 Rxi Pharmaceuticals Corp. Tripartite rnai constructs
WO2011133925A2 (en) * 2010-04-23 2011-10-27 Massachusetts Institute Of Technology Targeted and light-activated cytosolic drug delivery

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GARY B. BRAUN ET AL: "Laser-Activated Gene Silencing via Gold Nanoshell-siRNA Conjugates", ACS NANO, vol. 3, no. 7, 28 July 2009 (2009-07-28), pages 2007 - 2015, XP055161998, ISSN: 1936-0851, DOI: 10.1021/nn900469q *
QURESHI AMMAR T ET AL: "miR-148b-Nanoparticle conjugates for light mediated osteogenesis of human adipose stromal/stem ce", BIOMATERIALS, vol. 34, no. 31, 18 July 2013 (2013-07-18), pages 7799 - 7810, XP028683861, ISSN: 0142-9612, DOI: 10.1016/J.BIOMATERIALS.2013.07.004 *
YUKA MATSUSHITA-ISHIODORI ET AL: "Photoinduced RNA Interference", ACCOUNTS OF CHEMICAL RESEARCH, vol. 45, no. 7, 17 July 2012 (2012-07-17), pages 1039 - 1047, XP055099392, ISSN: 0001-4842, DOI: 10.1021/ar200227n *

Also Published As

Publication number Publication date
WO2015020769A2 (en) 2015-02-12

Similar Documents

Publication Publication Date Title
AR115692A2 (en) METHOD FOR THE PRODUCTION OF CONSTITUENT PROMOTERS OF TRANSGENIC PLANTS, CONSTRUCTS AND CELLS
WO2015089511A3 (en) Modified nucleic acid molecules and uses thereof
EP4257596A3 (en) Coumarin compounds and their uses as fluorescent labels
EP3065713A4 (en) Nanoscale carriers for the delivery or co-delivery of chemotherapeutics, nucleic acids and photosensitizers
WO2014205451A3 (en) Compositions and methods for modulation of target nucleic acids
WO2014021954A3 (en) Magneto-sensitive silk fibroin-based materials
WO2015196128A3 (en) Alternative nucleic acid molecules and uses thereof
IN2015DN01300A (en)
WO2015196130A3 (en) Alternative nucleic acid molecules and uses thereof
EP3441468A3 (en) Delivery methods and compositions for nuclease-mediated genome engineering
MY195237A (en) Process For The Preparation of a Zeolitic Material
MX2010009423A (en) Dryer configuration for production of polyester particles.
WO2016210337A3 (en) Methods of dewatering of alcoholic solutions via forward osmosis and related systems
WO2012076985A3 (en) Granzyme b inhibitor compositions, methods and uses for promoting wound healing
EA201401041A1 (en) NANOPARTICLES OF DUALLY DERIVATIZED CHITOSAN AND THE METHODS OF THEIR PRODUCTION AND APPLICATION FOR TRANSFER OF IN VIVO GENES
CL2013001621A1 (en) Nucleic acid regulatory molecule with definite specificity, expression construction comprising it, vector; microorganism, plant or animal cell; and method for the production of said molecule.
WO2014018785A3 (en) Biorefinery control system, components therefor, and methods of use
BR112013010169A8 (en) use of monascus in the production of organic acid.
WO2014038892A3 (en) Method and apparatus for preparing isopropyl alcohol
WO2015063090A3 (en) Drying of microorganisms
BR112014026709A2 (en) process for the production of methacrylic acid; and method for preparing polymer or copolymers.
WO2012037250A3 (en) Nano-deaggregated cellulose
WO2015020769A3 (en) Controllable nucleic acid delivery systems
BRPI1100062A2 (en) platelet-derived growth factor bb production promoter, and mesenchymal stem cell production accelerator, stem cell stabilizer and dermal regenerator comprising the same
BR112016029035A2 (en) process for the production of low-carbon coalescence aids

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14805700

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14805700

Country of ref document: EP

Kind code of ref document: A2